Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „tocilizumab“
Suchtreffer
Begriffe & Kennungen
RoActemra · 4.8 · Description of selected adverse reactions in sJIA patients The safety profile of intravenous tocilizumab in sJ
Eintrag öffnenRoActemra · 4.8 · GCA patients The safety of subcutaneous tocilizumab has been studied in one Phase III trial (WA28119) with 251
Eintrag öffnenRoActemra · 4.8 · GCA patients The safety of subcutaneous tocilizumab has been studied in one Phase III trial (WA28119) with 251
Eintrag öffnenRoActemra · 4.8 · Hepatic transaminase elevations During routine laboratory monitoring in the tocilizumab 12 month controlled cl
Eintrag öffnenRoActemra · 4.8 · Hepatic transaminase elevations During routine laboratory monitoring in the tocilizumab 12 month controlled cl
Eintrag öffnenRoActemra · 4.8 · Hepatic transaminase elevations During routine laboratory monitoring in the tocilizumab 6-month controlled cli
Eintrag öffnenRoActemra · 4.8 · Hepatic transaminase elevations During routine laboratory monitoring in the tocilizumab all exposure populatio
Eintrag öffnenRoActemra · 4.8 · Immunogenicity A total of 2 876 patients have been tested for anti-tocilizumab antibodies in the 6-month contr
Eintrag öffnenRoActemra · 4.8 · Immunogenicity A total of 2 876 patients have been tested for anti-tocilizumab antibodies in the 6-month contr
Eintrag öffnenRoActemra · 4.8 · Immunogenicity A total of 2876 patients have been tested for anti-tocilizumab antibodies in the 6-month contro
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In SC-I, a total of 625 patients treated with tocilizumab 162 mg weekly were tested for anti- t
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In SC-I, a total of 625 patients treated with tocilizumab 162 mg weekly were tested for anti- t
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In the subcutaneous trial (WA28118), 46 of the 51 (90.2 %) patients tested for anti-tocilizumab
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In the subcutaneous trial (WA28118), 46 of the 51 (90.2 %) patients tested for anti-tocilizumab
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In the subcutaneous trial 5.8 % [3/52] developed positive neutralising anti-tocilizumab antibod
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In the subcutaneous trial 5.8 % [3/52] developed positive neutralising anti-tocilizumab antibod
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In the tocilizumab subcutaneous weekly group, one patient (1.1 %, 1/95) developed positive neut
Eintrag öffnenRoActemra · 4.8 · Immunogenicity In the tocilizumab subcutaneous weekly group, one patient (1.1 %, 1/95) developed positive neut
Eintrag öffnenRoActemra · 4.8 · Immunogenicity One patient in the 10 mg/kg < 30 kg group developed positive anti-tocilizumab antibodies withou
Eintrag öffnenRoActemra · 4.8 · In 6-month controlled clinical trials, the rate of serious infections with tocilizumab 8 mg/kg plus DMARDs was
Eintrag öffnen